CJC-1295 (no DAC) + Ipamorelin 5mg/5mg research peptide

CJC-1295 without DAC plus ipamorelin (ghrelin receptor agonist): a research overview

Let's take this one slowly. This listing combines a GHRH-modeled peptide with ipamorelin, a ghrelin receptor agonist, so the two act on growth hormone release through different routes, and the literature for each looks quite different.

Please note: Snowman Research does not offer dosing information or usage guidance of any kind. Everything we list, this item included, is sold strictly for research purposes and nothing else.

Published findings

Human pharmacology for CJC-1295 describes a version that attaches to albumin once administered, giving it roughly an 8-day half-life. In healthy young men, a single administration raised baseline (trough) and average growth hormone along with IGF-I, while the natural pulse pattern of GH was kept ^[1]. Because this product is labeled "without DAC," those findings shouldn't be assumed to transfer. Ipamorelin was introduced in 1998 as the first selective GH secretagogue: in rat and swine studies it released GH about as potently as GHRP-6 but, unusually, without raising ACTH or cortisol ^[2]. A later phase 2 trial in 114 patients recovering from bowel surgery found it was well tolerated, though it did not significantly outperform placebo on time to a tolerated solid meal ^[3]. The pairing itself hasn't been studied in the cited work.

Mechanism at a glance

CJC-1295: a peptide modeled on growth hormone-releasing hormone (GHRH) ^[1]. Ipamorelin: a five-residue peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that triggers GH release through a GHRP-like receptor ^[2], described in surgical research as a ghrelin-receptor agonist ^[3].

Regulatory & WADA notes

The FDA lists CJC-1295 among substances formerly in compounding category 2 whose nominations were withdrawn, mentioning reported serious adverse events such as a faster heart rate and a systemic vasodilatory reaction. Ipamorelin acetate was placed in 503B category 2 on September 29, 2023; the agency references a published report of serious adverse events, including a death, after intravenous administration ^[4]. WADA's 2026 List names CJC-1295 (as a GHRH analogue) and ipamorelin (as a GH secretagogue) under S2.2.4, banned at all times ^[5].

Thanks for reading. Stay warm, and keep your bench notes tidy.

Further reading

1. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
2. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
3. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, human drug compounding web page (accessed Oct 4, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
5. World Anti-Doping Code International Standard: Prohibited List 2026 (in effect 1 January 2026). World Anti-Doping Agency, 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

For laboratory research use only. This product is not intended for human or veterinary use and is not an FDA-approved drug; nothing on this page is medical advice. You must be 21 or older to purchase.